Do analysts recommend SNTG or RAPP?

Rapport Therapeutics has a consensus target price of $64.29, indicating a potential upside of 53.24%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Sentage. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sentage 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rapport Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has better valuation and earnings, SNTG or RAPP?

Sentage has higher revenue and earnings than Rapport Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sentage $70K 71.66 -$2.28M N/A N/A Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A

Is SNTG or RAPP more profitable?

Sentage's return on equity of 0.00% beat Rapport Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sentage N/A N/A N/A Rapport Therapeutics N/A -29.02% -27.37%

Which has better earnings and valuation, BLTE or RAPP?

Belite Bio is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A

Is BLTE or RAPP more profitable?

Belite Bio's return on equity of -11.84% beat Rapport Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Rapport Therapeutics N/A -29.02% -27.37%

Does the media prefer BLTE or RAPP?

In the previous week, Belite Bio had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 4 mentions for Belite Bio and 2 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.86 beat Belite Bio's score of 0.43 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RAPP or LNTH?

In the previous week, Lantheus had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Rapport Therapeutics. Lantheus' average media sentiment score of 0.87 beat Rapport Therapeutics' score of 0.86 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LQDA or RAPP?

In the previous week, Liquidia had 11 more articles in the media than Rapport Therapeutics. MarketBeat recorded 13 mentions for Liquidia and 2 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.86 beat Liquidia's score of 0.83 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RAPP or AMRX?

In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 4 mentions for Amneal Pharmaceuticals and 2 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.86 beat Amneal Pharmaceuticals' score of 0.17 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rapport Therapeutics (RAPP) Competitors

$41.95 +0.56 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$42.19 +0.24 (+0.57%)

As of 07:30 PM Eastern

Compare

RAPP vs. SNTG, BLTE, LNTH, LQDA, and AMRX

Should you buy Rapport Therapeutics stock or one of its competitors? Rapport Therapeutics's main competitors and comparable companies include Sentage (SNTG), Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size.

How does Rapport Therapeutics compare to Sentage?

Sentage (NASDAQ:SNTG) and Rapport Therapeutics (NASDAQ:RAPP) are related companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Sentage has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Sentage's return on equity of 0.00% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sentage	N/A	N/A	N/A
Rapport Therapeutics	N/A	-29.02%	-27.37%

0.1% of Sentage shares are owned by institutional investors. 62.4% of Sentage shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sentage has higher revenue and earnings than Rapport Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sentage	$70K	71.66	-$2.28M	N/A	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

Rapport Therapeutics has a consensus target price of $64.29, indicating a potential upside of 53.24%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Sentage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sentage	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Rapport Therapeutics had 2 more articles in the media than Sentage. MarketBeat recorded 2 mentions for Rapport Therapeutics and 0 mentions for Sentage. Sentage's average media sentiment score of 1.43 beat Rapport Therapeutics' score of 0.86 indicating that Sentage is being referred to more favorably in the media.

Company	Overall Sentiment
Sentage	Positive
Rapport Therapeutics	Positive

Summary

Sentage beats Rapport Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Rapport Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Rapport Therapeutics (NASDAQ:RAPP) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Belite Bio's return on equity of -11.84% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Rapport Therapeutics	N/A	-29.02%	-27.37%

Belite Bio currently has a consensus price target of $218.73, indicating a potential upside of 28.40%. Rapport Therapeutics has a consensus price target of $64.29, indicating a potential upside of 53.24%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Belite Bio is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

In the previous week, Belite Bio had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 4 mentions for Belite Bio and 2 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.86 beat Belite Bio's score of 0.43 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Belite Bio and Rapport Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Lantheus?

Rapport Therapeutics (NASDAQ:RAPP) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Lantheus has a net margin of 17.69% compared to Rapport Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Lantheus	17.69%	28.10%	14.35%

Rapport Therapeutics presently has a consensus target price of $64.29, suggesting a potential upside of 53.24%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 7.25%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Rapport Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Lantheus had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Rapport Therapeutics. Lantheus' average media sentiment score of 0.87 beat Rapport Therapeutics' score of 0.86 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rapport Therapeutics has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Lantheus has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Lantheus	$1.56B	4.23	$233.56M	$4.14	24.35

Summary

Lantheus beats Rapport Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Rapport Therapeutics compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Rapport Therapeutics (NASDAQ:RAPP) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Liquidia has a net margin of 30.74% compared to Rapport Therapeutics' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Rapport Therapeutics	N/A	-29.02%	-27.37%

64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Liquidia has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$450.91M	13.58	-$68.92M	$1.37	49.92
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

In the previous week, Liquidia had 11 more articles in the media than Rapport Therapeutics. MarketBeat recorded 13 mentions for Liquidia and 2 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.86 beat Liquidia's score of 0.83 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia presently has a consensus target price of $98.08, indicating a potential upside of 43.42%. Rapport Therapeutics has a consensus target price of $64.29, indicating a potential upside of 53.24%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Liquidia has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

Summary

Liquidia beats Rapport Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Rapport Therapeutics compare to Amneal Pharmaceuticals?

Rapport Therapeutics (NASDAQ:RAPP) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Amneal Pharmaceuticals has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Amneal Pharmaceuticals	$3.12B	1.87	$72.06M	$0.49	37.31

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Rapport Therapeutics' net margin of 0.00%. Rapport Therapeutics' return on equity of -29.02% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Rapport Therapeutics presently has a consensus price target of $64.29, suggesting a potential upside of 53.24%. Amneal Pharmaceuticals has a consensus price target of $20.14, suggesting a potential upside of 10.19%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Rapport Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Rapport Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 4 mentions for Amneal Pharmaceuticals and 2 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.86 beat Amneal Pharmaceuticals' score of 0.17 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amneal Pharmaceuticals beats Rapport Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RAPP vs. The Competition

Export

Metric	Rapport Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.01B	$12.49B	$7.23B	$14.43B
Dividend Yield	N/A	2.64%	2.57%	12.31%
P/E Ratio	-13.80	797.36	274.13	25.56
Price / Sales	N/A	757.04	628.18	81.94
Price / Cash	N/A	85.42	76.40	50.90
Price / Book	4.12	10.61	10.51	6.31
Net Income	-$111.48M	$2.81B	$3.48B	$357.99M
7 Day Performance	-3.47%	0.30%	0.33%	0.29%
1 Month Performance	-13.36%	2.17%	-0.21%	-3.13%
1 Year Performance	59.51%	5.09%	22.63%	6.88%

Rapport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RAPP Rapport Therapeutics	2.3872 of 5 stars	$41.95 +1.4%	$64.29 +53.2%	+58.0%	$2.01B	N/A	N/A	84	Positive News Analyst Forecast
SNTG Sentage	1.0826 of 5 stars	$1.70 flat	N/A	-39.8%	$4.77M	$70K	N/A	20	Positive News Short Interest Decrease
BLTE Belite Bio	3.4228 of 5 stars	$192.85 -0.4%	$217.45 +12.8%	+152.9%	$7.80B	N/A	N/A	10	Gap Down High Trading Volume
LNTH Lantheus	3.624 of 5 stars	$100.44 -0.5%	$108.11 +7.6%	+93.4%	$6.59B	$1.54B	20.27	1,193
LQDA Liquidia	3.7845 of 5 stars	$67.68 -1.4%	$98.08 +44.9%	+163.0%	$6.15B	$158.32M	50.12	50	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapport Therapeutics (RAPP) Competitors

RAPP vs. SNTG, BLTE, LNTH, LQDA, and AMRX

How does Rapport Therapeutics compare to Sentage?

Summary

How does Rapport Therapeutics compare to Belite Bio?

Summary

How does Rapport Therapeutics compare to Lantheus?

Summary

How does Rapport Therapeutics compare to Liquidia?

Summary

How does Rapport Therapeutics compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapport Therapeutics (RAPP) Competitors

RAPP vs. SNTG, BLTE, LNTH, LQDA, and AMRX

How does Rapport Therapeutics compare to Sentage?

Which has more volatility & risk, SNTG or RAPP?

Is SNTG or RAPP more profitable?

Do institutionals and insiders believe in SNTG or RAPP?

Which has better valuation and earnings, SNTG or RAPP?

Do analysts recommend SNTG or RAPP?

Does the media prefer SNTG or RAPP?

Summary

How does Rapport Therapeutics compare to Belite Bio?

Which has more volatility & risk, BLTE or RAPP?

Do institutionals & insiders hold more shares of BLTE or RAPP?

Is BLTE or RAPP more profitable?

Do analysts rate BLTE or RAPP?

Which has better earnings and valuation, BLTE or RAPP?

Does the media prefer BLTE or RAPP?

Summary

How does Rapport Therapeutics compare to Lantheus?

Is RAPP or LNTH more profitable?

Do analysts rate RAPP or LNTH?

Does the media refer more to RAPP or LNTH?

Do insiders and institutionals hold more shares of RAPP or LNTH?

Which has more risk & volatility, RAPP or LNTH?

Which has better earnings & valuation, RAPP or LNTH?

Summary

How does Rapport Therapeutics compare to Liquidia?

Is LQDA or RAPP more profitable?

Do institutionals and insiders hold more shares of LQDA or RAPP?

Which has better earnings & valuation, LQDA or RAPP?

Does the media prefer LQDA or RAPP?

Do analysts prefer LQDA or RAPP?

Which has more risk & volatility, LQDA or RAPP?

Summary

How does Rapport Therapeutics compare to Amneal Pharmaceuticals?

Which has stronger valuation & earnings, RAPP or AMRX?

Do institutionals & insiders hold more shares of RAPP or AMRX?

Is RAPP or AMRX more profitable?

Do analysts prefer RAPP or AMRX?

Which has more risk and volatility, RAPP or AMRX?

Does the media refer more to RAPP or AMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools